<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03395977</url>
  </required_header>
  <id_info>
    <org_study_id>30309647</org_study_id>
    <nct_id>NCT03395977</nct_id>
  </id_info>
  <brief_title>Uric Acid Effects on Endothelium and Oxydative Stress</brief_title>
  <official_title>Differential Effects of Uric Acid and Xanthine Oxidoreductase on Endothelial Function and Oxydative Stress</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fonds Erasme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fonds National de la Recherche Scientifique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular disease is the leading cause of mortality worldwide. Endothelial dysfunction&#xD;
      (ED) is the main mechanism which leads to atherosclerosis, where the balance between pro and&#xD;
      antioxidant factors results in a decreased nitric oxide (NO) bioavailability. Xanthine&#xD;
      OxidoReductase (XOR) is one of the main generators of reactive oxygen species (ROS). Uric&#xD;
      acid (UA), a major antioxidant in human plasma and end product of purine metabolism, is&#xD;
      associated with cardiovascular diseases since many years; however the precise mechanisms&#xD;
      which relate UA to ED are still not well understood.&#xD;
&#xD;
      The purpose of this study is to unravel the XOR and UA pathways involved in ED. Three groups&#xD;
      of participants (young (&lt; 40 y) male healthy participants [1] ; male and female helthy&#xD;
      participants (40 to 65 y) [2] and patients with primary hypertension [3]) will be exposed to&#xD;
      febuxostat (a strong and selective XOR inhibitor), or recombinant uricase (which oxidizes UA&#xD;
      into allantoin) to vary UA levels and concomitantly control for confounding changes in XOR&#xD;
      activity. Oxidative stress will be estimated by several markers. Endothelial function will be&#xD;
      assessed by a laser Doppler imager in the presence of hyperthermia and endothelium&#xD;
      stimulators. This study is specifically designed to untie the respective effects of UA and&#xD;
      XOR pathways on oxidative stress and endothelial function in humans.&#xD;
&#xD;
      The investigators will test the following hypothesis:&#xD;
&#xD;
        1. An extremely low level of uric acid after uricase administration induces endothelial&#xD;
           dysfunction and oxydative stress,&#xD;
&#xD;
        2. A specific XO inhibitor limits unfavourable effects of the serum UA reduction elicited&#xD;
           by uricase administration,&#xD;
&#xD;
        3. Endothelial function and oxydative stress are further improved with febuxostat as&#xD;
           compared to placebo,&#xD;
&#xD;
        4. All these observations are more marked in hypertensives then in older participants than&#xD;
           in young healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goals of the research protocol are to clearly untie the respective roles of uric acid&#xD;
      (UA) and xanthine oxidoreductase (XOR) pathways on endothelial function and oxidative stress&#xD;
      in humans.&#xD;
&#xD;
      UA represents the end-product of purine metabolism due to the loss of uricase 15 million&#xD;
      years ago in humans. The selective advantage of this mutation could be the strong antioxidant&#xD;
      effect of UA (which represents more than 60% of the antioxidant plasmatic capacity). Many&#xD;
      recent epidemiological studies have showed a J-shape association between UA levels and&#xD;
      cardiovascular risk. An UA level lower than 3 mg/dl could be damageable due to the loss of&#xD;
      the antioxidant properties of UA. In contrast, hyperuricemia is associated with an increased&#xD;
      inflammation, insulin resistance, ED, platelet aggregation, left ventricle hypertrophy,&#xD;
      arterial vasodilatation impairment, aortic stiffness and intima-media thickness. However, the&#xD;
      association between UA and cardiovascular disease remains controversial because whether UA is&#xD;
      an independent risk factor for these illnesses is unclear.&#xD;
&#xD;
      Interventional studies:&#xD;
&#xD;
      Because the above-mentioned associations do not prove causation, several authors designed&#xD;
      interventional studies with the purpose to modify UA levels and determine if this affected&#xD;
      endothelial function and oxidative stress. The main limitation of these studies is that they&#xD;
      were unable to untie the effects of the synthesis of UA, of UA itself and of the activity of&#xD;
      XOR, on ROS production and endothelial function in humans.&#xD;
&#xD;
      This is because:&#xD;
&#xD;
        1. serum UA is a powerful plasmatic antioxidant,&#xD;
&#xD;
        2. but transformation of hypoxanthine to xanthine and xanthine to UA by XO generates&#xD;
           intracellular ROS,&#xD;
&#xD;
        3. moreover, in endothelial cells, UA reduces NO bioavailability by many ways (L-arginine&#xD;
           blockade and degradation, increased superoxide anion production, NOS inhibition, reduced&#xD;
           NOS genes expression and direct NO scavenging),&#xD;
&#xD;
        4. in addition, UA forms crystals in the endothelium wall which create a pro-inflammatory&#xD;
           and thrombotic state, increases smooth muscle cells proliferation and also insulin&#xD;
           resistance and inflammation in adipocytes,&#xD;
&#xD;
        5. finally, and most importantly, XO is inhibited by physiologic levels of UA (which acts&#xD;
           as an uncompetitive XO inhibitor).&#xD;
&#xD;
      In summary, the present protocol aims at testing the following hypothesis:&#xD;
&#xD;
        1. Experimental serum UA variations are correlated with endothelial function and oxydative&#xD;
           stress markers : an extremely low level after uricase administration induces ED and&#xD;
           oxydative stress,&#xD;
&#xD;
        2. A specific XO inhibitor (FX) limits unfavourable effects of the serum UA reduction&#xD;
           elicited by uricase administration, since this will hamper the feedback activation of XO&#xD;
           by a low UA level,&#xD;
&#xD;
        3. Endothelial function and oxydative stress are further improved with FX as compared to&#xD;
           placebo, because the first experimental condition results in a XO blockade,&#xD;
&#xD;
        4. All these observations are more marked in hypertensive patients then in older&#xD;
           participants than in young healthy subjects.&#xD;
&#xD;
      Data collection&#xD;
&#xD;
      Data collection from the participants will be collected informatically through a case report&#xD;
      form. The names and personnal data from the patients will be kept in a secret place or in a&#xD;
      password-protected file. All the data will be destroyed at the end of the study (including&#xD;
      blood and urine samples).&#xD;
&#xD;
      Statistical analysis&#xD;
&#xD;
      Statistical analysis will be performed using SPSS. Baseline characteristics will be compared&#xD;
      using a Student t test. Two-way repeated-measures ANOVAs will be used to detect significant&#xD;
      changes between sessions and groups. Statistical significance is assumed when p is &lt;0.05.&#xD;
      Sample size is not possible due to the lack of data of the effect of acute hypouricemia. We&#xD;
      estimate a minimum of 15 participants in each group.&#xD;
&#xD;
      Specific test will be used for non gaussian variables. Correlation test will be used if&#xD;
      necessary according the results of the first test.&#xD;
&#xD;
      Placebo-corrected values and comparisons of the delta will be used too.&#xD;
&#xD;
      Subgroups analyses will be performed for the study of population 2 and 3 (enrolled together).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 3, 2018</start_date>
  <completion_date type="Actual">February 27, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a prospective, randomized, placebo-controlled, double-blinded and 3 ways cross-over study.&#xD;
Three populations : healthy male subjects under 40 y [1] ; healthy male and female participants between 40 and 65 years [2] and subjects with hypertension [3]. Minimum 15 participants in each group are needed.&#xD;
The populations 2 and 3 will be studied together with subgroups analyses of the results for the status of hypertension, of treatment, age and gender.&#xD;
For 5 subjects in each group, we will perform a fourth session with Placebo PO and Rasburicase IV. That session will be non-randomized and blinded only for the subject.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Febuxostat and Rasburicase will be prepared by an independant pharmacist.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cutaneous perfusion by Laser Doppler (perfusion unit)</measure>
    <time_frame>24 hours after infusion of Uricase or Placebo</time_frame>
    <description>Perfusion unit (Laser Doppler Imager + iontophoresis of (ACh and SNP and hyperemia with ou without L-NAME). Assessment of endothelial function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Oxydative stress biomarkers from baseline to 30 min or 24 hours after infusion of Uricase or Placebo</measure>
    <time_frame>Baseline, 30 minutes and 24 hours after infusion of Uricase or Placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>24 hours after infusion of Uricase or Placebo</time_frame>
    <description>Carotido-femoral and carotido-radial pulse wave velocity and pulse wave analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure (mmHg)</measure>
    <time_frame>24 hours after infusion of Uricase or Placebo</time_frame>
    <description>Beat-to-beat measurements with Finapres and manually</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output (l-min)</measure>
    <time_frame>24 hours after infusion of Uricase or Placebo</time_frame>
    <description>Beat-to-beat measurements with Finapres</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in enzymes activity</measure>
    <time_frame>30 min and 24 hours after infusion of Uricase or Placebo</time_frame>
    <description>Xanthin oxydase activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in enzymes expression</measure>
    <time_frame>30 min and 24 hours after infusion of Uricase or Placebo</time_frame>
    <description>eNOS, NOX, XO we will incubate endothelial cells with plasma or serum from subjects. Then we will measure the sus-mentionned enzymes' expression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proteomic or metabolomic analysis</measure>
    <time_frame>30 min and 24 hours after infusion of Uricase or Placebo</time_frame>
    <description>We will perform proteomics or metabolomics analysis directly on serum from participants and also on lysate of endothelial cells pre-incubated with plasma or serum from participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renin-angiotensin activity</measure>
    <time_frame>Baseline, 30 minutes and 24 hours after infusion of Uricase or Placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary excretion of sodium</measure>
    <time_frame>Baseline, 30 minutes and 24 hours after infusion of Uricase or Placebo</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Oxidative Stress</condition>
  <condition>Endothelial Function</condition>
  <condition>Cardiovascular System</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebos PO and IV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PO : per os IV : intraveinously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Febuxostat PO and Placebo IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>240 mg a day for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Febuxostat PO And Rasburicase IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Febuxostat : 240 mg a day for 3 days. Uricase : 3 mg once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo PO And Rasburicase IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo : for 3 days. Uricase : 3 mg once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Lactose placebo for pills and saline for perfusion.</description>
    <arm_group_label>Febuxostat PO and Placebo IV</arm_group_label>
    <arm_group_label>Placebo PO And Rasburicase IV</arm_group_label>
    <arm_group_label>Placebos PO and IV</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>Febuxostat tablet.</description>
    <arm_group_label>Febuxostat PO And Rasburicase IV</arm_group_label>
    <arm_group_label>Febuxostat PO and Placebo IV</arm_group_label>
    <other_name>Adenuric</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasburicase</intervention_name>
    <description>Rasburicase injectable solution.</description>
    <arm_group_label>Febuxostat PO And Rasburicase IV</arm_group_label>
    <arm_group_label>Placebo PO And Rasburicase IV</arm_group_label>
    <other_name>Fasturtec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Phase 1 :&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 40 years&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Healthy volunteers&#xD;
&#xD;
          -  Non smoker for at least 6 months&#xD;
&#xD;
          -  Uric acid level in normal range (normouricemic group)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any diseases of one of the following systems: cardiovascular, digestive, hormonal,&#xD;
             urinary, pulmonary, rheumatic or immune.&#xD;
&#xD;
          -  Smoker, alcoholic&#xD;
&#xD;
          -  Participants should not take any chronic medicine nor vitamins or other antioxidants.&#xD;
&#xD;
          -  A G6PD deficit will be excluded as this is a contraindication to uricase&#xD;
             administration (hemolytic anemia).&#xD;
&#xD;
        Phase 2 :&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 40 and 65 years&#xD;
&#xD;
          -  Male or female (menopaused)&#xD;
&#xD;
          -  Healthy volunteers&#xD;
&#xD;
          -  Non smoker for at least 6 months&#xD;
&#xD;
          -  Uric acid level in normal range (normouricemic group)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any diseases of one of the following systems: cardiovascular, digestive, hormonal,&#xD;
             urinary, pulmonary, rheumatic or immune.&#xD;
&#xD;
          -  Smoker, alcoholic&#xD;
&#xD;
          -  Participants should not take any chronic medicine nor vitamins or other antioxidants.&#xD;
&#xD;
          -  A G6PD deficit will be excluded as this is a contraindication to uricase&#xD;
             administration (hemolytic anemia).&#xD;
&#xD;
        Phase 3 :&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 40 and 65 years&#xD;
&#xD;
          -  History of hypertension for more than 6 months&#xD;
&#xD;
          -  Non smoker or smoke stopped for at least for 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute coronary syndrome&#xD;
&#xD;
          -  Heart failure (LVEJ &lt; 40%)&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Active smoking&#xD;
&#xD;
          -  Gout&#xD;
&#xD;
          -  Chronic kidney disease stage superior to 3a&#xD;
&#xD;
          -  History of cerebrovascular thrombosis&#xD;
&#xD;
          -  Cirrhosis&#xD;
&#xD;
          -  Alcohol consumption more than 3 units/day&#xD;
&#xD;
          -  Participants should not take any chronic medicine nor vitamins or other antioxidants.&#xD;
&#xD;
          -  A G6PD deficit will be excluded as this is a contraindication to uricase&#xD;
             administration (hemolytic anemia).&#xD;
&#xD;
        The populations of phases 2 and 3 will be enrolled and studied together with subgroups&#xD;
        analyses of the results for the status of hypertension, of treatment, age and gender.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male or female for phases 2 and 3</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe van de Borne</last_name>
    <role>Study Director</role>
    <affiliation>Erasme hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erasme Hospital</name>
      <address>
        <city>Brussels</city>
        <state>Belgique</state>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 29, 2017</study_first_submitted>
  <study_first_submitted_qc>January 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2018</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasme University Hospital</investigator_affiliation>
    <investigator_full_name>Benjamin De Becker</investigator_full_name>
    <investigator_title>Investigator, Clinical Research</investigator_title>
  </responsible_party>
  <keyword>uric acid</keyword>
  <keyword>xanthin oxydoreductase</keyword>
  <keyword>febuxostat</keyword>
  <keyword>uricase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Febuxostat</mesh_term>
    <mesh_term>Rasburicase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

